NASDAQ:BLUE - bluebird bio Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$122.02 +1.34 (+1.11 %)
(As of 01/17/2019 06:26 AM ET)
Previous Close$120.68
Today's Range$121.25 - $129.61
52-Week Range$87.49 - $236.17
Volume1.19 million shs
Average Volume613,180 shs
Market Capitalization$6.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.41
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy; and Gritstone Oncology, Inc. to research, develop, and commercialize products for the treatment of cancer using cell therapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLUE
CUSIPN/A
Phone339-499-9300

Debt

Current Ratio13.11
Quick Ratio13.11

Price-To-Earnings

Sales & Book Value

Annual Sales$35.43 million
Price / Sales188.35
Price / Cash FlowN/A
Book Value$33.11 per share
Price / Book3.69

Profitability

Net Income$-335,640,000.00
Net Margins-1,326.02%
Return on Assets-26.59%

Miscellaneous

Employees479
Market Cap$6.60 billion
OptionableOptionable

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio Inc (NASDAQ:BLUE) issued its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($2.73) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($2.90) by $0.17. The biotechnology company had revenue of $11.50 million for the quarter, compared to analyst estimates of $6.90 million. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The company's revenue was up 49.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.73) earnings per share. View bluebird bio's Earnings History.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for bluebird bio.

What price target have analysts set for BLUE?

23 brokers have issued 1-year price objectives for bluebird bio's shares. Their predictions range from $120.00 to $250.00. On average, they expect bluebird bio's stock price to reach $191.9412 in the next year. This suggests a possible upside of 57.3% from the stock's current price. View Analyst Price Targets for bluebird bio.

What is the consensus analysts' recommendation for bluebird bio?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 1 sell rating, 7 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for bluebird bio.

What are Wall Street analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:
  • 1. According to Zacks Investment Research, "bluebird does not have any approved products in its portfolio and an unfavorable outcome from any of the ongoing studies will be huge setback. Shares have underperformed the industry in the last six months. Nevertheless, bluebird’s progress with its pipeline is encouraging. bluebird has an impressive pipeline of gene therapies for genetic diseases and cancer. LentiGlobin looks promising. The company’s collaboration with Regeneron is encouraging as it provides the company with funds. bluebird is also developing CAR T therapies in collaboration with Celgene for myeloma. The CAR T market holds potential and the successful development of the candidates will positively impact the company’s results. Celgene is expected to initiate a phase III study on bb2121 in third-line multiple myeloma shortly. Hence, we expect investors to focus on pipeline updates." (1/8/2019)
  • 2. Cantor Fitzgerald analysts commented, "We rate bluebird bio Neutral. BLUE, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for rare severe genetic diseases. Its product candidates include Lenti-D, which is in a pivotal clinical study for the treatment of cerebral adrenoleukodystrophy; LentiGlobin, which is in Phase 1/2 clinical studies for the treatment of beta thalassemia major and severe sickle cell disease (SCD); and bb2121 and bb21217 CAR-T, candidates in multiple myeloma. Valuation Summary We value bluebird bio based on a risk-adjusted NPV calculation of its clinical pipeline." (12/3/2018)
  • 3. Maxim Group analysts commented, "bluebird announced new data from its early- and late-stage programs will be presented at this year’s American Society of Hematology (ASH) meeting; gene therapy and CAR-T." (11/1/2018)

Has bluebird bio been receiving favorable news coverage?

Press coverage about BLUE stock has been trending positive on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. bluebird bio earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term.

Who are some of bluebird bio's key competitors?

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:
  • Mr. Nick Leschly, Pres, CEO & Director (Age 46)
  • Mr. Jeffrey T. Walsh, Chief Financial and Strategy Officer (Age 53)
  • Dr. Philip D. Gregory, Chief Scientific Officer (Age 48)
  • Mr. Jason F. Cole, Chief Legal Officer & Sec. (Age 46)
  • Dr. David M. Davidson, Chief Medical Officer (Age 55)

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different of institutional and retail investors. Top institutional investors include Retirement Systems of Alabama (0.04%), Virtu Financial LLC (0.01%) and Cornerstone Advisors Inc. (0.00%). Company insiders that own bluebird bio stock include Alison Cecily Finger, Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Kory James Wentworth, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.

Which major investors are buying bluebird bio stock?

BLUE stock was purchased by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Virtu Financial LLC and Cornerstone Advisors Inc.. View Insider Buying and Selling for bluebird bio.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $122.02.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $6.60 billion and generates $35.43 million in revenue each year. The biotechnology company earns $-335,640,000.00 in net income (profit) each year or ($7.71) on an earnings per share basis. bluebird bio employs 479 workers across the globe.

What is bluebird bio's official website?

The official website for bluebird bio is http://www.bluebirdbio.com.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]


MarketBeat Community Rating for bluebird bio (NASDAQ BLUE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  774 (Vote Outperform)
Underperform Votes:  421 (Vote Underperform)
Total Votes:  1,195
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe BLUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel